Dr. Bolla said the current study findings may significantly benefit clinicians. He also noted that some men may push for aggressive treatment and now long-term data are available to justify that approach in some cases. “To know that immediate postoperative irradiation can improve local control and biochemical disease-free survival may be considered as a strong argument for the patient who wants to win the battle against cancer. Nevertheless, the decision to proceed with adjuvant radiotherapy for high-risk prostate cancer after RP or to postpone radiotherapy as an early salvage procedure in case of biochemical relapse remains difficult,” Dr. Bolla told ChemotherapyAdvisor.com. “Ultimately, the decision to treat needs a multidisciplinary approach.”
1. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018-2027.
2. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181:956-962.
3. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol. 2009;27:2924-2930.
4. Efstathiou JA. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:1974-1976.